TELA Bio Statistics
Total Valuation
TELA Bio has a market cap or net worth of $70.52 million. The enterprise value is $78.68 million.
Important Dates
The last earnings date was Monday, August 11, 2025, after market close.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TELA Bio has 39.62 million shares outstanding. The number of shares has increased by 58.23% in one year.
| Current Share Class | 39.62M |
| Shares Outstanding | 39.62M |
| Shares Change (YoY) | +58.23% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 8.66% |
| Owned by Institutions (%) | 30.28% |
| Float | 18.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.92 |
| Forward PS | 0.73 |
| PB Ratio | 7.67 |
| P/TBV Ratio | 9.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.19, with a Debt / Equity ratio of 4.70.
| Current Ratio | 3.19 |
| Quick Ratio | 2.42 |
| Debt / Equity | 4.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.40 |
Financial Efficiency
Return on equity (ROE) is -676.41% and return on invested capital (ROIC) is -47.49%.
| Return on Equity (ROE) | -676.41% |
| Return on Assets (ROA) | -36.47% |
| Return on Invested Capital (ROIC) | -47.49% |
| Return on Capital Employed (ROCE) | -76.89% |
| Revenue Per Employee | $360,397 |
| Profits Per Employee | -$195,057 |
| Employee Count | 209 |
| Asset Turnover | 1.18 |
| Inventory Turnover | 1.96 |
Taxes
| Income Tax | -59,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.25% in the last 52 weeks. The beta is 0.93, so TELA Bio's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | -39.25% |
| 50-Day Moving Average | 1.85 |
| 200-Day Moving Average | 2.05 |
| Relative Strength Index (RSI) | 50.58 |
| Average Volume (20 Days) | 97,062 |
Short Selling Information
The latest short interest is 460,503, so 1.16% of the outstanding shares have been sold short.
| Short Interest | 460,503 |
| Short Previous Month | 448,140 |
| Short % of Shares Out | 1.16% |
| Short % of Float | 2.50% |
| Short Ratio (days to cover) | 5.85 |
Income Statement
In the last 12 months, TELA Bio had revenue of $75.32 million and -$40.77 million in losses. Loss per share was -$1.05.
| Revenue | 75.32M |
| Gross Profit | 51.08M |
| Operating Income | -37.27M |
| Pretax Income | -40.30M |
| Net Income | -40.77M |
| EBITDA | -36.21M |
| EBIT | -37.27M |
| Loss Per Share | -$1.05 |
Full Income StatementBalance Sheet
The company has $34.98 million in cash and $43.14 million in debt, giving a net cash position of -$8.17 million or -$0.21 per share.
| Cash & Cash Equivalents | 34.98M |
| Total Debt | 43.14M |
| Net Cash | -8.17M |
| Net Cash Per Share | -$0.21 |
| Equity (Book Value) | 9.18M |
| Book Value Per Share | 0.23 |
| Working Capital | 41.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$34.14 million and capital expenditures -$532,000, giving a free cash flow of -$34.68 million.
| Operating Cash Flow | -34.14M |
| Capital Expenditures | -532,000 |
| Free Cash Flow | -34.68M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
Gross margin is 67.81%, with operating and profit margins of -49.48% and -54.12%.
| Gross Margin | 67.81% |
| Operating Margin | -49.48% |
| Pretax Margin | -54.20% |
| Profit Margin | -54.12% |
| EBITDA Margin | -48.07% |
| EBIT Margin | -49.48% |
| FCF Margin | n/a |
Dividends & Yields
TELA Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -58.23% |
| Shareholder Yield | -58.23% |
| Earnings Yield | -57.81% |
| FCF Yield | -49.17% |
Analyst Forecast
The average price target for TELA Bio is $5.33, which is 199.44% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.33 |
| Price Target Difference | 199.44% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 23.91% |
| EPS Growth Forecast (5Y) | -28.49% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TELA Bio has an Altman Z-Score of -6.99 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.99 |
| Piotroski F-Score | 3 |
